Loading clinical trials...
Loading clinical trials...
Phase Ib/IIa Study of Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Conditions
Interventions
Chiauranib
Chidamide
Locations
1
China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
July 11, 2019
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2021
Last Updated
March 9, 2022
NCT06667687
NCT05623982
NCT03314974
NCT04586478
NCT05054257
NCT01746849
Lead Sponsor
Chipscreen Biosciences, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions